Smith & Nephew (LON:SN) Insider David King Buys 2,800 Shares of Stock

Smith & Nephew plc (LON:SN) insider David King bought 2,800 shares of the business’s stock in a transaction on Monday, August 18th. The shares were acquired at an average price of GBX 3,631 per share, with a total value of £101,668.

Smith & Nephew Price Performance

LON SN opened at GBX 1,367.50 on Thursday. The business’s fifty day simple moving average is GBX 1,169.45 and its two-hundred day simple moving average is GBX 1,097.90. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The company has a market capitalization of £14.99 billion, a PE ratio of 49.24, a PEG ratio of 0.46 and a beta of 0.62.

Wall Street Analysts Forecast Growth

SN has been the subject of a number of research reports. Berenberg Bank increased their price target on Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the company a “hold” rating in a research note on Thursday, August 7th. Deutsche Bank Aktiengesellschaft increased their price target on Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the company a “hold” rating in a research note on Wednesday, August 6th. Finally, JPMorgan Chase & Co. increased their price target on Smith & Nephew from GBX 1,357 to GBX 1,438 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of GBX 1,379.33.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.